Shares of Second Sight Medical Products Inc (NASDAQ:EYES) have earned a consensus broker rating score of 1.00 (Strong Buy) from the one brokers that provide coverage for the stock, Zacks Investment Research reports. One investment analyst has rated the stock with a strong buy rating.

Brokers have set a one year consensus target price of $5.00 for the company and are expecting that the company will post ($0.14) earnings per share for the current quarter, according to Zacks. Zacks has also given Second Sight Medical Products an industry rank of 81 out of 255 based on the ratings given to related companies.

EYES has been the subject of several recent analyst reports. Zacks Investment Research upgraded Second Sight Medical Products from a “sell” rating to a “hold” rating in a research note on Tuesday, October 9th. HC Wainwright set a $5.00 price objective on Second Sight Medical Products and gave the stock a “buy” rating in a research note on Wednesday, August 8th.

In other news, Director Gregg Williams acquired 15,520 shares of the stock in a transaction that occurred on Monday, September 24th. The stock was purchased at an average cost of $1.86 per share, for a total transaction of $28,867.20. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last quarter, insiders purchased 3,727,524 shares of company stock valued at $5,853,523 and sold 23,777 shares valued at $41,543. 34.70% of the stock is owned by company insiders.

Shares of EYES traded down $0.05 during mid-day trading on Friday, hitting $1.57. The company’s stock had a trading volume of 169,085 shares, compared to its average volume of 214,788. Second Sight Medical Products has a one year low of $1.05 and a one year high of $2.58. The stock has a market capitalization of $108.66 million, a price-to-earnings ratio of -2.66 and a beta of 3.07.

Second Sight Medical Products (NASDAQ:EYES) last issued its earnings results on Tuesday, August 7th. The medical device company reported ($0.12) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.02. The firm had revenue of $1.91 million during the quarter, compared to analysts’ expectations of $2.21 million. Second Sight Medical Products had a negative return on equity of 432.45% and a negative net margin of 418.82%. Equities research analysts anticipate that Second Sight Medical Products will post -0.58 EPS for the current fiscal year.

About Second Sight Medical Products

Second Sight Medical Products, Inc develops, manufactures and markets prosthetic devices. Its product the Argus II System, treats outer retinal degenerations and employs electrical stimulation to bypass degenerated photoreceptor cells and to stimulate remaining viable retinal cells thereby inducing visual perception in blind individuals.

Read More: How to Use a Moving Average for TradingĀ 

Get a free copy of the Zacks research report on Second Sight Medical Products (EYES)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Second Sight Medical Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Second Sight Medical Products and related companies with's FREE daily email newsletter.